Cytosorbents (CTSO) 10-Q2013 Q1 Quarterly report

Filed: 15 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absence, addressing, adequacy, amended, apply, assessment, attempt, autoimmune, bead, BetaSorb, billion, biocompatible, BOD, bodily, broadly, cancelled, capable, cartridge, catheterization, chemotherapy, Christopher, committee, complement, confirm, consumer, contrast, ContrastSorb, correct, costly, counter, Cramer, CT, deadly, DEFICIENCY, detrimental, Director, DLT, dose, dosing, drug, DrugSorb, efficacy, expert, extracting, fact, fairly, fluid, forward, GAAP, goal, growth, healthcare, hemocompatible, HemoDefend, hemofiltration, hemoperfusion, identified, identify, identifying, II, imaging, inappropriate, ineffective, inflammation, Innovation, integration, intensive, interventional, IV, Jersey, Johnson, joined, labor, Lack, larger, lead, leading, liver, longer, MBA, mechanical, mentioned, met, mortality, nephropathy, Notwithstanding, officially, optimism, overdose, oversight, path, pharmaceutical, pivotal, pool, population, previously, profitability, projected, promulgated, prospective, protected, prove, publicly, radiology, randomized, REDEEMABLE, regional, remediate, rent, requisite, restricted, revise, role, saving, Senior, septic, set, shape, similar, size, small, sorbent, subgroup, submit, submitted, supervision, syndrome, transfusion, undergoing, undue, unmet, unwanted, update, variety, ventilation, Venture, volume, worldwide

Removed: acceptance, annum, assigned, Assuming, beneficial, calculation, carried, CEO, CFO, Chief, Codification, commencement, commercializing, comparing, comparison, competition, component, Concurrent, continued, convert, country, coverage, demonstrate, dependence, detailed, distribution, embedded, equal, exhibit, expand, FASB, feature, focusing, gather, governmental, guarantee, holder, hospitalized, human, initiated, involve, jurisdiction, label, marketplace, obtained, priced, promissory, proposed, provision, purpose, quotient, Reform, repaid, resulting, scope, technological, testing, tolerated, Topic, unexpected, unknown, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CTSO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cytosorbents Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Phillip Chan, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2013

By:

/s/ Phillip Chan

Phillip Chan

Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.